<DOC>
	<DOCNO>NCT00930670</DOCNO>
	<brief_summary>There conflict evidence literature suggest use proton pump inhibitor ( PPIs ) , and/or statin interfere clopidogrel antiplatelet effect result adverse cardiovascular outcome patient treat coronary artery stent dual antiplatelet therapy . The primary aim study determine effect various currently use PPI platelet aggregation patient undergo percutaneous coronary intervention ( PCI ) treat dual antiplatelet therapy . The secondary aim study evaluate statin 2C19*2 polymorphism modulate effect PPI clopidogrel efficacy .</brief_summary>
	<brief_title>Evaluation Influence Statins Proton Pump Inhibitors Clopidogrel Antiplatelet Effects</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Subject must 18 year age old Bare metal stent implantation Discharged dual antiplatelet therapy least 60 day Written inform consent Patients consent participate study Premenopausal woman use contraceptive method without negative pregnancy test past week Patients treat plan treated oral anticoagulant Present treatment clear indication treatment PPI H2 antagonists Allergy intolerance study medication include ranitidine , Proton pump inhibitor , atorvastatin , rosuvastatin , aspirin and/or clopidogrel Patient treat strong CYP2C19 interact drug History bleeding diathesis , evidence active abnormal bleeding within 30 day enrollment History intracranial hemorrhage intracranial surgery last 3 month History gastrointestinal ulcer last 3 month Any serious illness condition investigator feel would influence impact therapy subject Known platelet count &lt; 100000/mm3 time enrollment within 24 hour prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>ranitidine</keyword>
	<keyword>pantoprazole</keyword>
	<keyword>esomeprazole</keyword>
	<keyword>omeprazole</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>statin</keyword>
	<keyword>clopidogrel resistance</keyword>
	<keyword>antiplatelet therapy</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>stent</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>drug interaction</keyword>
	<keyword>drug resistance</keyword>
	<keyword>genetic polymorphism</keyword>
</DOC>